The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases - PubMed (original) (raw)

Review

The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases

A J Docherty et al. Trends Biotechnol. 1992 Jun.

Abstract

Uncontrolled matrix metalloproteinase activity is thought to be a cause of the tissue damage observed in many disease processes. None of the drugs currently in use can prevent tissue destruction, and strategies for the development of synthetic inhibitors have been hampered by a poor understanding of the biochemistry of matrix metalloproteinases. Recent cDNA cloning efforts and characterization of recombinant human matrix metalloproteinases have permitted structure-function analysis of the enzymes and their inhibitors. Progress in this area should help indicate a route to rational strategies for designing lead therapeutic compounds.

PubMed Disclaimer

Similar articles

• Metalloproteinases and their inhibitors in matrix remodeling.
  Matrisian LM. Matrisian LM. Trends Genet. 1990 Apr;6(4):121-5. doi: 10.1016/0168-9525(90)90126-q. Trends Genet. 1990. PMID: 2132731 Review.
• Structural biochemistry and activation of matrix metalloproteases.
  Kleiner DE Jr, Stetler-Stevenson WG. Kleiner DE Jr, et al. Curr Opin Cell Biol. 1993 Oct;5(5):891-7. doi: 10.1016/0955-0674(93)90040-w. Curr Opin Cell Biol. 1993. PMID: 8240832 Review.
• Metalloproteinases and tissue damage.
  Murphy G, Docherty AJ, Hembry RM, Reynolds JJ. Murphy G, et al. Br J Rheumatol. 1991;30 Suppl 1:25-31. Br J Rheumatol. 1991. PMID: 1991237 Review. No abstract available.
• The matrix metalloproteinases and their inhibitors.
  Murphy G, Docherty AJ. Murphy G, et al. Am J Respir Cell Mol Biol. 1992 Aug;7(2):120-5. doi: 10.1165/ajrcmb/7.2.120. Am J Respir Cell Mol Biol. 1992. PMID: 1497900 Review.
• Regulation of matrix metalloproteinase activity.
  Murphy G, Willenbrock F, Crabbe T, O'Shea M, Ward R, Atkinson S, O'Connell J, Docherty A. Murphy G, et al. Ann N Y Acad Sci. 1994 Sep 6;732:31-41. doi: 10.1111/j.1749-6632.1994.tb24722.x. Ann N Y Acad Sci. 1994. PMID: 7978800 Review. No abstract available.

Cited by

• The architecture of cancer.
  Waxman J, Wasan H. Waxman J, et al. BMJ. 1992 Nov 28;305(6865):1306-7. doi: 10.1136/bmj.305.6865.1306. BMJ. 1992. PMID: 1483071 Free PMC article. No abstract available.
• Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes.
  Khan AR, James MN. Khan AR, et al. Protein Sci. 1998 Apr;7(4):815-36. doi: 10.1002/pro.5560070401. Protein Sci. 1998. PMID: 9568890 Free PMC article. Review.
• Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
  Zheng MH, Fan Y, Panicker A, Smith A, Robertson T, Wysocki S, Robbins P, Papadimitriou JM, Wood DJ. Zheng MH, et al. Am J Pathol. 1995 Dec;147(6):1559-66. Am J Pathol. 1995. PMID: 7495280 Free PMC article.
• Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter.
  Bian J, Sun Y. Bian J, et al. Mol Cell Biol. 1997 Nov;17(11):6330-8. doi: 10.1128/MCB.17.11.6330. Mol Cell Biol. 1997. PMID: 9343394 Free PMC article.
• Postnatal LPS Challenge Impacts Escape Learning and Expression of Plasticity Factors Mmp9 and Timp1 in Rats: Effects of Repeated Training.
  Trofimov A, Strekalova T, Mortimer N, Zubareva O, Schwarz A, Svirin E, Umriukhin A, Svistunov A, Lesch KP, Klimenko V. Trofimov A, et al. Neurotox Res. 2017 Aug;32(2):175-186. doi: 10.1007/s12640-017-9720-2. Epub 2017 Apr 18. Neurotox Res. 2017. PMID: 28421528 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information